
What's Taking the FDA So Long?
About this episode
Experts say that a “fully approved” designation for the vaccines could have sweeping effects. Broader vaccination mandates, inclusion for new age groups, and reassurance for those hesitant to take a vaccine without the designation. As calls for approval grow louder and more urgent, the Food and Drug Administration is yet to give its blessing. What’s happening inside the FDA as they work toward this milestone?
Guest: Sarah Owermohle, health care reporter at Politico
Host:
Lizzie O’Leary
Need to set up your Slate Plus feed? If you subscribed through Slate.com, check out our FAQ at slate.com/podcastfaqs for easy instructions. Members subscribed via Apple Podcasts get automatic access—no setup required.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time What Next: TBD | Tech, power, and the future publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from What Next: TBD | Tech, power, and the future

Meta Settled. Is it a "Reckoning?"
What Next: TBD | Tech, power, and the future

A.I. Enshittifies Everything (Still)
What Next: TBD | Tech, power, and the future

Can the Midterms Withstand Prediction Markets?
What Next: TBD | Tech, power, and the future

Are Flock Cameras Watching You?
What Next: TBD | Tech, power, and the future